

Irene Slavec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6902563/publications.pdf>

Version: 2024-02-01

127
papers

5,988
citations

126907

33
h-index

82547

72
g-index

127
all docs

127
docs citations

127
times ranked

8933
citing authors

#	ARTICLE	IF	CITATIONS
1	The assessment of executive functioning in pediatric patients with posterior fossa tumors: A recommendation to combine caregiver-based ratings and performance-based tests. <i>Developmental Neurorehabilitation</i> , 2022, 25, 19-28.	1.1	2
2	Unique Finding of a Primary Central Nervous System Neuroendocrine Carcinoma in a 5-Year-Old Child: A Case Report. <i>Frontiers in Neuroscience</i> , 2022, 16, 810645.	2.8	3
3	Impact of childhood cerebellar tumor surgery on cognition revealed by precuneus hyperconnectivity. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac050.	0.7	1
4	Evaluating the diagnostic validity of the cerebellar cognitive affective syndrome (CCAS) in pediatric posterior fossa tumor patients. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	2
5	QOL-27. Sociocultural variables have a major impact on participation in patients treated for pediatric posterior fossa tumors. <i>Neuro-Oncology</i> , 2022, 24, i139-i139.	1.2	0
6	PATH-09. Liquid biopsy of cerebrospinal fluid enables detecting and monitoring of <i>MYC/MYCN</i> amplification in pediatric CNS malignancies. <i>Neuro-Oncology</i> , 2022, 24, i160-i160.	1.2	0
7	IMG-03. Impact of childhood cerebellar tumor surgery on cognition: Can fMRI serve as a surrogate marker?. <i>Neuro-Oncology</i> , 2022, 24, i77-i77.	1.2	0
8	DDEL-05. Intraventricular therapy with topotecan is feasible and safe: Experience in 50 pediatric patients with various malignant brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i34-i35.	1.2	0
9	SURG-02. The site of origin of medulloblastoma: Does the neurosurgical perspective support the current concept from molecular data?. <i>Neuro-Oncology</i> , 2022, 24, i142-i142.	1.2	0
10	QOL-30. Positive Effects of a psychological preparation program for MRI in children with cognitive issues – how to best meet the patients’ needs. <i>Neuro-Oncology</i> , 2022, 24, i140-i140.	1.2	0
11	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial. <i>Neuro-Oncology</i> , 2022, 24, i104-i104.	1.2	1
12	QOL-24. Evaluating the diagnostic validity & predictive value of the Cerebellar Cognitive Affective Syndrome (CCAS) in pediatric posterior fossa tumour patients. <i>Neuro-Oncology</i> , 2022, 24, i138-i139.	1.2	0
13	Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas. <i>Acta Neurochirurgica</i> , 2021, 163, 2025-2035.	1.7	13
14	Novel Insights into Diagnosis, Biology and Treatment of Primary Diffuse Leptomeningeal Melanomatosis. <i>Journal of Personalized Medicine</i> , 2021, 11, 292.	2.5	15
15	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. <i>Acta Neuropathologica</i> , 2021, 142, 339-360.	7.7	14
16	RARE-20. A RARE CASE OF A PRIMARY CENTRAL NERVOUS SYSTEM NEUROENDOCRINE CARCINOMA AND SUCCESSFULL THERAPY IN A FIVE-YEAR-OLD CHILD. <i>Neuro-Oncology</i> , 2021, 23, i45-i45.	1.2	0
17	HGG-06. EARLY GABAERGIC NEURONAL LINEAGE DEFINES DEPENDENCIES IN HISTONE H3 G34R/V GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, i18-i18.	1.2	0
18	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	1.2	22

#	ARTICLE	IF	CITATIONS
19	Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage. <i>Neurosurgery</i> , 2020, 86, 478-484.	1.1	2
20	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	7.7	13
21	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. <i>Cancer Cell</i> , 2020, 38, 44-59.e9.	16.8	94
22	Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma. <i>Journal of Personalized Medicine</i> , 2020, 10, 290.	2.5	18
23	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. <i>Acta Neuropathologica Communications</i> , 2020, 8, 78.	5.2	28
24	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 944-954.	1.2	25
25	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	1.6	58
26	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
27	Editorial: Precision/Personalized Pediatric Oncology and Immune Therapies: Rather Customize Than Randomize. <i>Frontiers in Oncology</i> , 2020, 10, 377.	2.8	3
28	MBCL-43. RECURRENT MEDULLOBLASTOMA â€“ LONG-TERM SURVIVAL WITH A â€œMEMMATâ€•BASED ANTIANGIOGENIC APPROACH. <i>Neuro-Oncology</i> , 2020, 22, iii397-iii397.	1.2	5
29	Potential Importance of Early Focal Radiotherapy Following Gross Total Resection for Long-Term Survival in Children With Embryonal Tumors With Multilayered Rosettes. <i>Frontiers in Oncology</i> , 2020, 10, 584681.	2.8	11
30	ETMR-17. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF ETMR PATIENT SAMPLES. <i>Neuro-Oncology</i> , 2020, 22, iii326-iii326.	1.2	0
31	MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT. <i>Neuro-Oncology</i> , 2020, 22, iii388-iii389.	1.2	0
32	DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii284-iii284.	1.2	0
33	ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). <i>Neuro-Oncology</i> , 2020, 22, iii324-iii325.	1.2	0
34	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii312.	1.2	0
35	HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii351-iii352.	1.2	0
36	ETMR-08. INTERNATIONAL CONSENSUS PROTOCOL FOR EMBRYONAL TUMOR WITH MULTILAYER ROSETTES. <i>Neuro-Oncology</i> , 2020, 22, iii324-iii324.	1.2	0

#	ARTICLE	IF	CITATIONS
37	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. <i>Neuro-Oncology</i> , 2020, 22, ii76-ii77.	1.2	0
38	TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma. <i>Acta Neuropathologica Communications</i> , 2019, 7, 128.	5.2	26
39	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	28.9	1,408
40	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	27.8	273
41	Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand?. <i>Journal of Neuro-Oncology</i> , 2019, 145, 177-184.	2.9	36
42	High impact of miRNA-4521 on FOXM1 expression in medulloblastoma. <i>Cell Death and Disease</i> , 2019, 10, 696.	6.3	27
43	Management of choroid plexus tumors – an institutional experience. <i>Acta Neurochirurgica</i> , 2019, 161, 745-754.	1.7	34
44	RARE-12. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR). <i>Neuro-Oncology</i> , 2019, 21, vi223-vi224.	1.2	0
45	Constitutional mismatch repair deficiency – associated brain tumors: report from the European C4CMMRD consortium. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz033.	0.7	23
46	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. <i>Neuro-Oncology</i> , 2019, 21, vi194-vi194.	1.2	0
47	GENE-45. DISSECTING THE DRIVERS OF ADULT H3K27M-GLIOMAS AT THE SINGLE-CELL LEVEL. <i>Neuro-Oncology</i> , 2019, 21, vi107-vi107.	1.2	0
48	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. <i>Journal of Medical Genetics</i> , 2019, 56, 53-62.	3.2	40
49	Childhood supratentorial ependymomas with <i>YAP1</i> – <i>MAML1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. <i>Brain Pathology</i> , 2019, 29, 205-216.	4.1	75
50	Personalized Treatment of H3K27M-Mutant Pediatric Diffuse Gliomas Provides Improved Therapeutic Opportunities. <i>Frontiers in Oncology</i> , 2019, 9, 1436.	2.8	50
51	Cerebellar pilocytic astrocytoma in childhood: Investigating the long-term impact of surgery on cognitive performance and functional outcome. <i>Developmental Neurorehabilitation</i> , 2018, 21, 1-8.	1.1	20
52	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	12.6	461
53	Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 552-559.	2.0	7
54	Monitoring of plexiform neurofibroma in children and adolescents with neurofibromatosis type 1 by [¹⁸ F]FDG – PET imaging. Is it of value in asymptomatic patients?. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26733.	1.5	35

#	ARTICLE	IF	CITATIONS
55	EAPH-11. INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE, AQUEOUS CYTARABINE AND TOPOTECAN IS FEASIBLE AND SAFE: EXPERIENCE IN 26 PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i67-i67.	1.2	2
56	MBCL-28. PREDISPOSITION OF WNT-ACTIVATED MEDULLOBLASTOMA FOR PRIMARY INTRATUMORAL HEMORRHAGE. <i>Neuro-Oncology</i> , 2018, 20, i122-i122.	1.2	0
57	MBCL-40. UNFAVORABLE CLINICAL COURSE OF A WNT-ACTIVATED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i125-i126.	1.2	0
58	NSRG-19. CSF DISTURBANCES AFTER TRANSCALLOSAL RESECTION: ARE THERE PREDICTING FACTORS?. <i>Neuro-Oncology</i> , 2018, 20, i149-i149.	1.2	0
59	NSRG-20. LONG-TERM SUPRATENTORIAL WHITE MATTER CHANGES AND COGNITIVE FUNCTION FOLLOWING CEREBELLAR TUMOUR RESECTIONS IN CHILDHOOD. <i>Neuro-Oncology</i> , 2018, 20, i149-i149.	1.2	0
60	INNV-36. A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY MAY PROLONG SURVIVAL FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. <i>Neuro-Oncology</i> , 2018, 20, vi145-vi145.	1.2	0
61	EPID-09. CMMRD (CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY) ASSOCIATED-BRAIN TUMORS: REPORT FROM THE EUROPEAN C4CMMRD CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i82-i82.	1.2	0
62	MBCL-27. RESPONSE OF RECURRENT MALIGNANT CHILDHOOD CNS TUMORS TO A MEMMAT BASED METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY VARIES DEPENDENT ON TUMOR TYPE: EXPERIENCE IN 71 PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, i122-i122.	1.2	4
63	MBRS-28. SINGLE-CELL TRANSCRIPTOME ANALYSIS OF MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, i134-i134.	1.2	0
64	Best practices for the use of intracerebroventricular drug delivery devices. <i>Molecular Genetics and Metabolism</i> , 2018, 124, 184-188.	1.1	44
65	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. <i>Neuro-Oncology</i> , 2018, 20, i72-i72.	1.2	4
66	QOL-43. CEREBELLAR MUTISM, NEUROCOGNITIVE AND ACADEMIC OUTCOME IN A CONSECUTIVE SAMPLE OF PEDIATRIC CEREBELLAR TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, i166-i166.	1.2	0
67	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	2.9	42
68	Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies. <i>Drugs in R and D</i> , 2017, 17, 469-474.	2.2	6
69	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. <i>Neuro-Oncology</i> , 2017, 19, 1183-1194.	1.2	31
70	From Symptom to Diagnosis – The Prediagnostic Symptomatic Interval of Pediatric Central Nervous System Tumors in Austria. <i>Pediatric Neurology</i> , 2017, 76, 27-36.	2.1	24
71	Do we still need IQ-scores? Misleading interpretations of neurocognitive outcome in pediatric patients with medulloblastoma: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2017, 135, 361-369.	2.9	13
72	Applying the International Classification of Functioning – Children and Youth Version to Pediatric Neuro-oncology. <i>Journal of Child Neurology</i> , 2017, 32, 23-28.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration. <i>Pediatric Neurology</i> , 2017, 67, 23-35.	2.1	117
74	Neuronal correlates of cognitive function in patients with childhood cerebellar tumor lesions. <i>PLoS ONE</i> , 2017, 12, e0180200.	2.5	10
75	Highlights of Children with Cancer UK's Workshop on Drug Delivery in Paediatric Brain Tumours. <i>Ecanermedalscience</i> , 2016, 10, 630.	1.1	2
76	Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994-2011. <i>Cancer Epidemiology</i> , 2016, 42, 72-81.	1.9	33
77	Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. <i>Acta Neuropathologica Communications</i> , 2016, 4, 88.	5.2	44
78	MB-70MEMMAT - A PHASE II STUDY OF METRONOMIC AND TARGETED ANTI-ANGIOGENESIS THERAPY FOR CHILDREN WITH RECURRENT/PROGRESSIVE MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii113.1-iii113.	1.2	3
79	BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016, 18, vi27-vi28.	1.2	1
80	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
81	Future paradigms for precision oncology. <i>Oncotarget</i> , 2016, 7, 46813-46831.	1.8	23
82	ANGI-14 UPDATE ON A METRONOMIC ANTIANGIOGENIC COMBINATION THERAPY FOR RECURRENT MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR. <i>Neuro-Oncology</i> , 2015, 17, v44.1-v44.	1.2	0
83	Genomic Alterations in Atypical Teratoid/Rhabdoid Tumors: The Medical University of Vienna Experience. <i>Cancer Genetics</i> , 2014, 207, 456.	0.4	0
84	Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium - Care for CMMRD (C4CMMRD). <i>Journal of Medical Genetics</i> , 2014, 51, 355-365.	3.2	351
85	Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012. <i>Cancer Medicine</i> , 2014, 3, 91-100.	2.8	99
86	Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. <i>Journal of Neuro-Oncology</i> , 2014, 120, 139-145.	2.9	58
87	Pharmacokinetics and Toxicity of Intrathecal Liposomal Cytarabine in Children and Adolescents Following Age-Adapted Dosing. <i>Clinical Pharmacokinetics</i> , 2014, 53, 165-173.	3.5	28
88	High plasma-GFAP levels in metastatic myxopapillary ependymoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 359-363.	2.9	8
89	Advantages of an ICF-Based Approach in School Reintegration of Pediatric Brain Tumor Patients: The School Participation Scales (S-PS-24/7). <i>Journal of Cancer Therapy</i> , 2013, 04, 825-834.	0.4	8
90	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 511-517.	1.5	98

#	ARTICLE	IF	CITATIONS
91	Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med. <i>Amino Acids</i> , 2012, 42, 2149-2163.	2.7	7
92	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. <i>Acta Neuropathologica</i> , 2011, 122, 787-790.	7.7	27
93	Incidence of atypical teratoid/rhabdoid tumors in children. <i>Cancer</i> , 2010, 116, 5725-5732.	4.1	126
94	Feasibility and tolerability of bevacizumab in children with primary CNS tumors. <i>Pediatric Blood and Cancer</i> , 2010, 54, 681-686.	1.5	33
95	Primary central nervous system lymphoma: a clinicopathological study of 75 cases. <i>Pathology</i> , 2010, 42, 547-552.	0.6	42
96	Neurotrophin 3/TrkC-regulated proteins in the human medulloblastoma cell line DAOY. <i>Electrophoresis</i> , 2009, 30, 540-549.	2.4	9
97	Tumor stabilization under treatment with imatinib in progressive hypothalamic-chiasmatic glioma. <i>Pediatric Blood and Cancer</i> , 2009, 52, 476-480.	1.5	11
98	Pharmacokinetics and Safety of Intrathecal Liposomal Cytarabine in Children Aged <3 Years. <i>Clinical Pharmacokinetics</i> , 2009, 48, 265-271.	3.5	34
99	Synthesis, Chaperoning, and Metabolism of Proteins Are Regulated by NT-3/TrkC Signaling in the Medulloblastoma Cell Line DAOY. <i>Journal of Proteome Research</i> , 2008, 7, 1932-1944.	3.7	9
100	Mitosis-Dependent Protein Expression in Neuroblastoma Cell Line N1E-115. <i>Journal of Proteome Research</i> , 2008, 7, 3412-3422.	3.7	4
101	Papillary glioneuronal tumor. <i>Neuropathology</i> , 2007, 27, 468-473.	1.2	33
102	Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma. <i>Lancet Oncology</i> , The, 2006, 7, 521-523.	10.7	76
103	The medulloblastoma cell line DAOY but not eleven other tumor cell lines expresses minichromosome maintenance protein 4. <i>Cancer Letters</i> , 2006, 238, 76-84.	7.2	4
104	Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY. <i>Cancer Letters</i> , 2006, 241, 235-249.	7.2	11
105	Immunohistochemical Analysis of INI1 Protein in Malignant Pediatric CNS Tumors: Lack of INI1 in Atypical Teratoid/Rhabdoid Tumors and in a Fraction of Primitive Neuroectodermal Tumors without Rhabdoid Phenotype. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1462-1468.	3.7	166
106	Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. <i>Neuropathology</i> , 2006, 26, 393-399.	1.2	11
107	Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. <i>Acta Neuropathologica</i> , 2005, 109, 211-216.	7.7	34
108	Survivin Expression in Intracranial Ependymomas and Its Correlation With Tumor Cell Proliferation and Patient Outcome. <i>American Journal of Clinical Pathology</i> , 2005, 124, 543-549.	0.7	32

#	ARTICLE	IF	CITATIONS
109	Validation of Hypothetical Nucleic Acid Binding Proteins in Human Bronchial Epithelial, Mesothelial, Amnion, Kidney and Lymphocyte Cell Lines by Proteomics. <i>Current Proteomics</i> , 2004, 1, 297-313.	0.3	3
110	Ki-67 Immunolabeling Index Is an Accurate Predictor of Outcome in Patients With Intracranial Ependymoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 914-920.	3.7	78
111	Proteomic Determination of Metabolic Protein Expression in Ten Different Tumor Cell Lines. <i>Cancer Genomics and Proteomics</i> , 2004, 1, 311-338.	2.0	0
112	Proteomic Profiling of Signaling Proteins in Ten Different Tumor Cell Lines. <i>Cancer Genomics and Proteomics</i> , 2004, 1, 427-454.	2.0	0
113	Protein Profiling of the Supratentorial Primitive Neuroectodermal Tumor (PNET) Cell Line PFSK-1. <i>Cancer Genomics and Proteomics</i> , 2004, 1, 125-136.	2.0	1
114	Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2003, 64, 239-247.	2.9	60
115	Protein profiles of medulloblastoma cell lines DAOY and D283: Identification of tumor-related proteins and principles. <i>Proteomics</i> , 2003, 3, 1781-1800.	2.2	48
116	Proteomic characterization of the human cortical neuronal cell line HCN-2. <i>Journal of Chemical Neuroanatomy</i> , 2003, 26, 171-178.	2.1	25
117	Proliferative activity as measured by MIB-1 labeling index and long-term outcome of cerebellar juvenile pilocytic astrocytomas. <i>Journal of Neuro-Oncology</i> , 2002, 58, 141-146.	2.9	17
118	Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. <i>Acta Neuropathologica</i> , 2000, 100, 101-105.	7.7	70
119	Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children. <i>Journal of Neuro-Oncology</i> , 1999, 42, 143-150.	2.9	13
120	Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. <i>Journal of Neuro-Oncology</i> , 1998, 38, 213-218.	2.9	44
121	Mutation analysis and loss of heterozygosity of PEDF in central nervous system primitive neuroectodermal tumors. , 1997, 72, 277-282.		10
122	p53 gene mutations in pediatric brain tumors. <i>Medical and Pediatric Oncology</i> , 1995, 25, 431-436.	1.0	65
123	Exon scanning for mutations of the <i>h2f2</i> gene in pediatric ependymomas, rhabdoid tumors and meningiomas. <i>International Journal of Cancer</i> , 1995, 64, 243-247.	5.1	54
124	Deletion mapping and candidate gene analysis of chromosome 17 in primitive neuroectodermal tumors of the CNS. <i>Cancer Genetics and Cytogenetics</i> , 1995, 84, 133.	1.0	0
125	Acute megakaryocytic leukemia in children: clinical, immunologic, and cytogenetic findings in two patients. <i>Cancer</i> , 1991, 68, 2266-2272.	4.1	28
126	B-cell differentiation pattern of cutaneous lymphomas in infancy and childhood. <i>Cancer</i> , 1988, 61, 303-308.	4.1	37

#	ARTICLE	IF	CITATIONS
127	Sociocultural variables have a major impact on participation in patients treated for paediatric posterior fossa tumours. Child: Care, Health and Development, 0, , .	1.7	1